Literature DB >> 1120309

Detection of antibody and complement complexed in vivo on membranes of human cancer cells by mixed hemadsorption techniques.

K Irie, R F Irie, D L Morton.   

Abstract

The mixed hemadsorption (MHA) techniques demonstrated antibody and complement fixed in vivo to the surface of human cancer cells. Tumors from 12 cancer patients and normal tissues from 5 cancer patients and 8 patients with cerebrovascular or cardiac diseases were collected from biopsy and autopsy for in vitro testing. Antiserum to human whole immunoglobulins and antiserum to human C3 were used in the MHA techniques. Positive MHA patterns were demonstrated on the surface of cancer cells by both methods. Positive reactions ranged from 12 to 32% in mixed hemadsorption for anitbody detection and from 10 to 34% in mixed hemadsorption for complement component 3 detection. Normal tissues obtained from cancer patients or from patients who died of causes other than cancer rarely exhibited distinct MHA reactivity. Collectively, the data suggest that most human cancers are antigenic in the autologous host and that tumor-associated antigens of cancer cells react in vivo with their humoral antibody to fix complement.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1120309

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Editorial: Complement activation and disease.

Authors: 
Journal:  Br Med J       Date:  1976-02-21

2.  Serological analysis of cell surface antigens of malignant human brain tumors.

Authors:  M Pfreundschuh; H Shiku; T Takahashi; R Ueda; J Ransohoff; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

3.  [Monoclonal antibodies against surface antigens of laryngeal carcinoma cells (author's transl)].

Authors:  H P Zenner
Journal:  Arch Otorhinolaryngol       Date:  1981

4.  Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.

Authors:  T E Carey; T Takahashi; L A Resnick; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1976-09       Impact factor: 11.205

5.  Autologous antibodies to human bladder cancer.

Authors:  H B Grossman; G Wedemeyer; J Stein
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Further characterization of a melanoma-specific protein from human urine.

Authors:  C Bennett; K B Cooke
Journal:  Br J Cancer       Date:  1980-05       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.